Literature DB >> 18403656

Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival.

Aryeh Fischer1, Jeffrey J Swigris2, Steve D Groshong3, Carlyne D Cool3, Hakan Sahin4, David A Lynch4, Douglas Curran-Everett5, JoAnn Z Gillis6, Richard T Meehan6, Kevin K Brown2.   

Abstract

PURPOSES: To evaluate the pathologic patterns, clinical features, and survival among subjects with scleroderma (ie, systemic sclerosis [SSc]) and clinically significant interstitial lung disease (ILD) evaluated at an ILD center.
METHODS: Retrospective cohort study of all SSc patients who had been referred for further evaluation of ILD and had undergone surgical lung biopsy. Clinical data were abstracted by review of the medical record, and lung biopsy specimens were reviewed and classified according to current pathologic criteria.
RESULTS: All patients presented with significant respiratory symptoms. Twenty-two of 27 subjects had surgical lung biopsy-proven ILD, and 5 subjects had miscellaneous non-ILD patterns. Of those subjects with ILD, 64% (14 of 22 subjects) had a nonspecific interstitial pneumonia (NSIP) pathologic pattern (fibrotic NSIP, 13 subjects; cellular NSIP, 1 subject), and 36% (8 of 22 subjects) had the usual interstitial pneumonia (UIP) pattern. Subjects with NSIP were younger (median age, 42 vs 58 years, respectively; p = 0.003), but no differences were noted in pulmonary physiology (FVC: NSIP group, 52% predicted; UIP group, 65% predicted; p = 0.22; diffusing capacity of the lung for carbon monoxide: NSIP group, 40% predicted; UIP group, 42% predicted; p = 1.0). All patients had limited skin involvement. The Scl-70 antibody was absent among those assessed (NSIP group, 0 of 10 subjects; UIP group, 0 of 7 subjects). All patients were treated with cytotoxic therapy. The median survival time for those with NSIP was 15.3 years (5,596 days) compared with 3 years (1,084 days) for those with UIP (p = 0.07 [log-rank test]).
CONCLUSIONS: In SSc patients with limited cutaneous disease and clinically significant ILD, fibrotic NSIP and UIP are the predominant pathologic patterns. Those with the UIP pattern of disease had a trend toward shorter survival time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403656     DOI: 10.1378/chest.08-0053

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  46 in total

Review 1.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 2.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

Review 3.  Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.

Authors:  Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

4.  Interstitial Pneumonia with Autoimmune Features: Overview of proposed criteria and recent cohort characterization.

Authors:  Cathryn T Lee; Justin M Oldham
Journal:  Clin Pulm Med       Date:  2017-09

5.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

6.  Interstitial Lung Disease Associated with Connective Tissue Diseases.

Authors:  Ruben A Peredo; Vivek Mehta; Scott Beegle
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Cyclophosphamide for connective tissue disease-associated interstitial lung disease.

Authors:  Hayley Barnes; Anne E Holland; Glen P Westall; Nicole Sl Goh; Ian N Glaspole
Journal:  Cochrane Database Syst Rev       Date:  2018-01-03

8.  Influence of interstitial lung disease on outcome in systemic sclerosis: a population-based historical cohort study.

Authors:  Philippe R Bauer; Dante N Schiavo; Thomas G Osborn; David L Levin; Jennifer St Sauver; Andrew C Hanson; Darrell R Schroeder; Jay H Ryu
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

Review 9.  Imaging lung disease in systemic sclerosis.

Authors:  Diane Strollo; Jonathan Goldin
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 10.  Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.

Authors:  Anupama Shahane
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.